CLChao-Wen Lu

Chao-Wen Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chao-Wen Lu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hybrid and Open Surgical Tracheostomy in a Single-Center Retrospective Cohort

    by Chao-Wen Lu, Xu-Heng Chiang, Pei-Hsing Chen, Yu-Cheng Chang, Hsien-Chi Liao, Shih-Chi Ku, Hsao-Hsun Hsu

    Background/Objectives: Hybrid tracheostomy combines direct surgical exposure with guidewire dilation. We describe institutional procedure allocation and observed outcomes of hybrid and open surgical tracheostomy (ST). Methods: This single-center retrospective cohort included 294 procedures (243 hybrid and 51 open ST) performed from July 2020 to February 2022. Analyses included the existing 1:1 propensity-matched sample and descriptive stratification by recorded preoperative difficult-airway status. Results: The mean operative time was shorter with hybrid tracheostomy in the overall cohort (15.4 ± 8.9 vs. 24.8 ± 40.7 min, p = 0.001). After matching, the difference was not statistically significant (14.1 ± 7.0 vs. 29.0 ± 49.6 min, p = 0.092; independent-group Student’s t-test). Overall weaning success was 55.1%; no statistically significant between-group difference was observed after matching. In the exploratory difficult-airway subgroup, complications occurred after 1/29 hybrid procedures (3.4%) and 2/10 open ST procedures (20.0%). These small, selected subgroups do not establish a preferred technique. Conclusions: In this single-center retrospective study, hybrid tracheostomy appeared to be a safe and feasible option in selected patients. However, preoperative assessment for a difficult airway is essential to guide individualized procedural planning.

  • Open Access

    Epidermal Growth Factor Receptor (EGFR) Amplification May Lead to Invalid Cobas EGFR Mutation Test v2 Results

    by Min-Shu Hsieh, Tze-Chun Hung, Hsien-Neng Huang, Chao-Wen Lu, Hsiang-Wei Hu, Jin-Yao Lai, Wen-Yao Lee, Jin-Shing Chen

    Background/Objectives: The cobas EGFR test v2, used for detecting EGFR mutations, can yield invalid results due to internal control (IC) issues, such as “IC not detected”, “IC out of range: high Ct value”, or “IC out of range: low Ct value”. This study aimed to examine the incidence of invalid cobas results and explored the mechanism behind low IC Ct values. Methods: We retrospectively reviewed invalid cases, linking undetectable or high IC Ct values to inadequate DNA from small biopsies, as determined by conducting a pathological review. Cases with low IC Ct values were further tested, with the hypothesis of EGFR amplification confirmed using Sanger sequencing, the Idylla assay, next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH). Results: Among 4148 cases, the incidence of invalid results was 0.99% (41/4148). In four cases with low IC Ct values, EGFR amplification was confirmed using alternative methods with successful cobas testing on diluted DNA. Conclusions: These findings suggest that EGFR amplification, rather than specimen inadequacy, is the cause of low IC Ct results, making rebiopsy unnecessary. Alternative assays or diluted DNA allow for successful EGFR testing.

  • Open Access

    Quantification of Resection Margin following Sublobar Resection in Lung Cancer Patients through Pre- and Post-Operative CT Image Comparison: Utilizing a CT-Based 3D Reconstruction Algorithm

    by Yu-Hsuan Lin, Li-Wei Chen, Hao-Jen Wang, Min-Shu Hsieh, Chao-Wen Lu, Jen-Hao Chuang, Yeun-Chung Chang, Jin-Shing Chen, Chung-Ming Chen, Mong-Wei Lin

    Sublobar resection has emerged as a standard treatment option for early-stage peripheral non-small cell lung cancer. Achieving an adequate resection margin is crucial to prevent local tumor recurrence. However, gross measurement of the resection margin may lack accuracy due to the elasticity of lung tissue and interobserver variability. Therefore, this study aimed to develop an objective measurement method, the CT-based 3D reconstruction algorithm, to quantify the resection margin following sublobar resection in lung cancer patients through pre- and post-operative CT image comparison. An automated subvascular matching technique was first developed to ensure accuracy and reproducibility in the matching process. Following the extraction of matched feature points, another key technique involves calculating the displacement field within the image. This is particularly important for mapping discontinuous deformation fields around the surgical resection area. A transformation based on thin-plate spline is used for medical image registration. Upon completing the final step of image registration, the distance at the resection margin was measured. After developing the CT-based 3D reconstruction algorithm, we included 12 cases for resection margin distance measurement, comprising 4 right middle lobectomies, 6 segmentectomies, and 2 wedge resections. The outcomes obtained with our method revealed that the target registration error for all cases was less than 2.5 mm. Our method demonstrated the feasibility of measuring the resection margin following sublobar resection in lung cancer patients through pre- and post-operative CT image comparison. Further validation with a multicenter, large cohort, and analysis of clinical outcome correlation is necessary in future studies.


  • Open Access

    Deep Learning Analysis for Predicting Tumor Spread through Air Space in Early-Stage Lung Adenocarcinoma Pathology Images

    by De-Xiang Ou, Chao-Wen Lu, Li-Wei Chen, Wen-Yao Lee, Hsiang-Wei Hu, Jen-Hao Chuang, Mong-Wei Lin, Kuan-Yu Chen, Ling-Ying Chiu, Jin-Shing Chen, et al.

    The presence of spread through air spaces (STASs) in early-stage lung adenocarcinoma is a significant prognostic factor associated with disease recurrence and poor outcomes. Although current STAS detection methods rely on pathological examinations, the advent of artificial intelligence (AI) offers opportunities for automated histopathological image analysis. This study developed a deep learning (DL) model for STAS prediction and investigated the correlation between the prediction results and patient outcomes. To develop the DL-based STAS prediction model, 1053 digital pathology whole-slide images (WSIs) from the competition dataset were enrolled in the training set, and 227 WSIs from the National Taiwan University Hospital were enrolled for external validation. A YOLOv5-based framework comprising preprocessing, candidate detection, false-positive reduction, and patient-based prediction was proposed for STAS prediction. The model achieved an area under the curve (AUC) of 0.83 in predicting STAS presence, with 72% accuracy, 81% sensitivity, and 63% specificity. Additionally, the DL model demonstrated a prognostic value in disease-free survival compared to that of pathological evaluation. These findings suggest that DL-based STAS prediction could serve as an adjunctive screening tool and facilitate clinical decision-making in patients with early-stage lung adenocarcinoma.


  • Open Access

    Clinicopathological Features and Significance of Epidermal Growth Factor Receptor Mutation in Surgically Resected Early-Stage Lung Adenocarcinoma

    by Chao-Wen Lu, Mong-Wei Lin, Xu-Heng Chiang, Hsao-Hsun Hsu, Min-Shu Hsieh, Jin-Shing Chen

    The clinicopathological presentation of early-stage lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations has been seldom studied. Our study enrolled patients with stage I and II lung adenocarcinoma between January 2014 and December 2017 at the National Taiwan University Hospital. Clinicopathological features and prognosis were retrospectively reviewed and analyzed depending on EGFR mutation status. EGFR mutations were detected in 622 (60%) out of 1034 patients. Compared to the group without EGFR mutations, the group with EGFR mutations had more patients above 65 years of age (p < 0.001), more non-lepidic histological subtypes (p < 0.001), higher CEA levels (p = 0.044), higher grade of pleural (p = 0.02) and lymphovascular (p = 0.001) invasion, higher histological grade (p < 0.001), and a more advanced pathological stage (p = 0.022). In multivariate analysis, there was no significant difference in PFS or OS between the EGFR mutant and wild-type groups. In subtype analysis, the tumors with an L858R mutation had a more lepidic predominant histological type (p = 0.019) and less lymphovascular invasion (p = 0.011). No significant differences in PFS or OS were detected between the exon 19 deletion and L858R mutation groups. In early-stage lung adenocarcinoma, EGFR mutation may be considered as a treatment response predictor for tyrosine kinase inhibitors, instead of a predictor of clinical prognosis.